HD-DAE方案治疗晚期肺癌的临床效果  

Effect of HD-DAE Protocol in Chemotherapy of Advanced Lung Cancer

作　　者：华新民[1] 徐力[1] 任宪伟[1] 段贵新[1] 吴清泽 刘建阳[1] 王启文[1] 刘炀[1] 肖震[1] 卢卫平[1] 

机构地区：[1]吉林省肿瘤医院胸一科,长春市130031

出　　处：《中国肿瘤临床》1997年第8期608-611,共4页Chinese Journal of Clinical Oncology

摘　　要：作者自1989年2月以来应用HD－DAE（DDP100mg～120mg／m2第1天静滴；ADM40mg／m2第1天静注；VP－16100mg第1～5天静滴）方案治疗晚期肺癌，可评价者232例，每个病例经1～6周期，平均1．3周期化疗，疗效达CR24例（10．3％），PR173例（74．6％），有效缓解率84．9％。在CR病例中有7例在行支气管镜复查时细胞学或／和病理学为阴性，另有24例在化疗后得以行肺切除手术，其中3例手术标本病灶及转移淋巴结仅见癌细胞残形，失去细胞结构。经6年观察现本组病例中位缓解期14个月，中位生存期18个月。1年生存率84．1％，2年生存率68．1％，3年生存率46．6％，4年生存率10．3％，5年生存率0．86％。其毒性反应达Ⅲ、Ⅳ期者在胃肠道15．5％，肾脏2．6％，骨髓造血系统25．9％，其中与化疗有关死亡3例（1．3％）。实践证明本方案对晚期肺癌具有较高的临床缓解率，使生存期得以显著延长，是晚期肺癌有效的联合化疗方案。作者还对方案中各抗癌药协同合作机制进行了分析。From February 1989,protocol HD-DAE(DDP 100-120mg/m2 i. v.and ADM 40mg/m2 i. v. on day 1;VP-16 100mg i. v. on day 1～5)was used in the treatment of late stage lung cancer patients. Of 232 evaluable cases,all received 1～6 cycles,average 1. 3 cycles. CR was achieved in 24 (10.3%),PR in 133 (74. 6%),overall 84.9%. No cancer cells were found in 7 of the CR cases on bronchoscopic cytologic examination. Pneumonectomy was performed following completion of chemotherapy in 24 cases. Vestige of cancer cells with loss of normal structure were found histologicaIly only in three specimens. Over a 6-year follow-up observation,a median symptom alleviation duration of 14 months and a median survival duration of 18 months were noted. The 1 to 5-year survival rates were 84.1%, 68.1%,46.6%, 10.3% and 0.86% respectively. Toxic reaction of Ⅲ-Ⅳ degree with G-I tract, kidney and bone marrow were 15. 5%, 2.6%, 25.9% respectively. Three death cases were related to chemotherapy (1. 3%).It is thought that HD-DAE protocol is advisable in the treatment of late stage cancer patients and that it prolonged patient's survival.

关 键 词：肺肿瘤 药物疗法 联合化疗 

分 类 号：R734.205[医药卫生—肿瘤]